Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period

Abstract Background Postpartum iron deficiency anemia (PPIDA) is highly prevalent in developing countries where it constitutes an important cause of maternal morbidity and mortality. Potential determinants of PPIDA are prepartum iron deficiency or iron deficiency anemia in association with severe bl...

Full description

Bibliographic Details
Main Authors: Edu Antoine, Claudia Mehedintu, Mihai Mitran, Doru Diculescu
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Pregnancy and Childbirth
Subjects:
Online Access:https://doi.org/10.1186/s12884-023-05658-7
_version_ 1797822597329584128
author Edu Antoine
Claudia Mehedintu
Mihai Mitran
Doru Diculescu
author_facet Edu Antoine
Claudia Mehedintu
Mihai Mitran
Doru Diculescu
author_sort Edu Antoine
collection DOAJ
description Abstract Background Postpartum iron deficiency anemia (PPIDA) is highly prevalent in developing countries where it constitutes an important cause of maternal morbidity and mortality. Potential determinants of PPIDA are prepartum iron deficiency or iron deficiency anemia in association with severe blood loss during delivery. We investigated the efficacy of oral Sucrosomial® iron for recover from mild-to-moderate PPIDA. Methods This pilot study was conducted in three medical centers in Romania. Adult women (≥ 18y) with mild (hemoglobin [Hb] 9–11 g/dL) or moderate (Hb 7–9 g/dL) PPIDA diagnosed at screening (2–24 h after delivery) were eligible. Women with mild PPIDA received oral Sucrosomial® iron (Pharmanutra, S.p.A, Italy) once daily (30 mg elemental iron per capsule) for 60 days. Those with moderate PPIDA received oral Sucrosomial® iron twice daily (60 mg elemental iron) for 10 days, followed by a 50-day course of oral Sucrosomial® iron once daily (30 mg elemental iron). Laboratory parameters, as well as subjective clinical symptoms using a 3-point Likert Scale, were assessed at baseline and on study days 10, 30 and 60. Results Sixty anemic women entered the study, but three were missed during follow-up. At day 60, a Hb rise was observed in both groups (+ 3.6 ± 1.5 g/dL; p < 0.01), 81% experienced correction of anemia (Hb ≥ 12 g/dL), 36% achieved a ferritin concentration ≥ 30 ng/mL (p < 0.05), and 54% a transferrin saturation (TSAT) ≥ 20% (p < 0.01). For women still anemic at day 60, mean Hb was close to normality (11.3 ± 0.8 g/dL). Resolution of IDA-associated clinical symptoms was already observed just 10 days after treatment initiation. No patient discontinued treatment due to gastrointestinal adverse events. Conclusions Sucrosomial® iron was shown to be potentially effective and well tolerated at treating mild and moderate PPIDA. These results encourage the use of oral Sucrosomial® iron as a treatment option for PPIDA, but larger studies with longer follow-up are warrant.
first_indexed 2024-03-13T10:11:26Z
format Article
id doaj.art-4f45693223914f079dc499ae302c13e2
institution Directory Open Access Journal
issn 1471-2393
language English
last_indexed 2024-03-13T10:11:26Z
publishDate 2023-05-01
publisher BMC
record_format Article
series BMC Pregnancy and Childbirth
spelling doaj.art-4f45693223914f079dc499ae302c13e22023-05-21T11:29:41ZengBMCBMC Pregnancy and Childbirth1471-23932023-05-012311910.1186/s12884-023-05658-7Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum periodEdu Antoine0Claudia Mehedintu1Mihai Mitran2Doru Diculescu3Department of Obstetrics-Gynecology, Clinical Hospital “Nicolae Malaxa”Department of Obstetrics-Gynecology, Clinical Hospital “Nicolae Malaxa”Department of Obstetrics-Gynecology, Clinical Hospital “Panait Sirbu”Department of Obstetrics-Gynecology, Clinical Hospital “Dominic Stanca”Abstract Background Postpartum iron deficiency anemia (PPIDA) is highly prevalent in developing countries where it constitutes an important cause of maternal morbidity and mortality. Potential determinants of PPIDA are prepartum iron deficiency or iron deficiency anemia in association with severe blood loss during delivery. We investigated the efficacy of oral Sucrosomial® iron for recover from mild-to-moderate PPIDA. Methods This pilot study was conducted in three medical centers in Romania. Adult women (≥ 18y) with mild (hemoglobin [Hb] 9–11 g/dL) or moderate (Hb 7–9 g/dL) PPIDA diagnosed at screening (2–24 h after delivery) were eligible. Women with mild PPIDA received oral Sucrosomial® iron (Pharmanutra, S.p.A, Italy) once daily (30 mg elemental iron per capsule) for 60 days. Those with moderate PPIDA received oral Sucrosomial® iron twice daily (60 mg elemental iron) for 10 days, followed by a 50-day course of oral Sucrosomial® iron once daily (30 mg elemental iron). Laboratory parameters, as well as subjective clinical symptoms using a 3-point Likert Scale, were assessed at baseline and on study days 10, 30 and 60. Results Sixty anemic women entered the study, but three were missed during follow-up. At day 60, a Hb rise was observed in both groups (+ 3.6 ± 1.5 g/dL; p < 0.01), 81% experienced correction of anemia (Hb ≥ 12 g/dL), 36% achieved a ferritin concentration ≥ 30 ng/mL (p < 0.05), and 54% a transferrin saturation (TSAT) ≥ 20% (p < 0.01). For women still anemic at day 60, mean Hb was close to normality (11.3 ± 0.8 g/dL). Resolution of IDA-associated clinical symptoms was already observed just 10 days after treatment initiation. No patient discontinued treatment due to gastrointestinal adverse events. Conclusions Sucrosomial® iron was shown to be potentially effective and well tolerated at treating mild and moderate PPIDA. These results encourage the use of oral Sucrosomial® iron as a treatment option for PPIDA, but larger studies with longer follow-up are warrant.https://doi.org/10.1186/s12884-023-05658-7PostpartumIron deficiencySucrosomial® ironWomenMild anaemiaModerate anaemia
spellingShingle Edu Antoine
Claudia Mehedintu
Mihai Mitran
Doru Diculescu
Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
BMC Pregnancy and Childbirth
Postpartum
Iron deficiency
Sucrosomial® iron
Women
Mild anaemia
Moderate anaemia
title Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
title_full Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
title_fullStr Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
title_full_unstemmed Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
title_short Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period
title_sort sucrosomial r iron effectiveness in recovering from mild and moderate iron deficiency anemia in the postpartum period
topic Postpartum
Iron deficiency
Sucrosomial® iron
Women
Mild anaemia
Moderate anaemia
url https://doi.org/10.1186/s12884-023-05658-7
work_keys_str_mv AT eduantoine sucrosomialironeffectivenessinrecoveringfrommildandmoderateirondeficiencyanemiainthepostpartumperiod
AT claudiamehedintu sucrosomialironeffectivenessinrecoveringfrommildandmoderateirondeficiencyanemiainthepostpartumperiod
AT mihaimitran sucrosomialironeffectivenessinrecoveringfrommildandmoderateirondeficiencyanemiainthepostpartumperiod
AT dorudiculescu sucrosomialironeffectivenessinrecoveringfrommildandmoderateirondeficiencyanemiainthepostpartumperiod